Jazz Pharmaceuticals, Inc.
Corporate Headquarters Fourth Floor, Connaugh
One Burlington Road
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals plc is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. We have a diverse portfolio of products and product candidates, with a focus in the areas of sleep and hematology/oncology. We also support commercial products in therapeutic areas where we can meaningfully address serious medical needs.
As part of our unwavering commitment to improve patients’ lives, we continue to expand our commercial product portfolio and our research and development pipeline in therapeutic areas that can leverage our unique expertise. We do this through a growth strategy of growing sales of the existing products in our portfolio; acquiring additional differentiated products that are on the market or product candidates that are in late-stage development; and pursuing focused development of a pipeline of post-discovery differentiated product candidates.
We have a strong patient-focused culture at Jazz Pharmaceuticals that our employees believe in and pursue every day. It is clearly identified through our mission, vision and core values. Each member of our team makes integral contributions and is working toward a common goal to improve patients' lives. Everything we do at Jazz Pharmaceuticals is focused on three things:
• Putting patients first
• Being a great place to work
• Living our core values — integrity, collaboration, passion, pursuit of excellence and innovation
335 articles with Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals plc announced that the U.S. Drug Enforcement Agency has designated solriamfetol, also known as Sunosi, as a Schedule IV medicine.
Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development
Jazz Pharmaceuticals plc announced the appointment of Robert Iannone, M.D., M.S.C.E., as executive vice president, research and development, effective May 29, 2019.
Data to be presented underscore commitment to developing life-changing medicines in hematology/oncology for people with limited or no treatment options
Received FDA Approval of Sunosi for Excessive Daytime Sleepiness (EDS) Associated with Narcolepsy or Obstructive Sleep Apnea (OSA)
Jazz Pharmaceuticals plc announced that the company will be webcasting its corporate presentations at two upcoming investor conferences.
Jazz Pharmaceuticals plc announced that it will report its 2019 first quarter financial results on Tuesday, May 7, 2019, after the close of the financial markets.
The government charged the three companies with using charitable foundations they financially supported to finance copays of Medicare and Medicaid patients, which is a violation of law.
Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness
JZP-258 achieves primary and key secondary endpoints demonstrating highly statistically significant differences in weekly number of cataplexy attacks and Epworth Sleepiness Scale scores compared to placebo
Shares of Jazz Pharmaceuticals are climbing in premarket trading following a late Wednesday announcement that the U.S. Food and Drug Administration granted approval for Sunosi, a treatment for people with narcolepsy.
Jazz Pharmaceuticals Announces U.S. FDA Approval of Sunosi™ (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor approved by the FDA to improve wakefulness in adults living with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea
It’s a busy week for the U.S. Food and Drug Administration (FDA) with quite a number of pending drug approvals, several of which were delayed for a variety of reasons. Here’s a look.
Jazz Pharmaceuticals plc announced financial results for the full year and the fourth quarter of 2018 and provided financial guidance for 2019.
Jazz Pharmaceuticals plc announced that Anne O'Riordan, Senior Managing Director, Life Sciences of Accenture, was appointed to its Board of Directors, effective February 14, 2019.
Jazz Pharmaceuticals to Report 2018 Fourth Quarter and Full Year Financial Results on February 26, 2019
Jazz Pharmaceuticals plc announced that it will report its 2018 fourth quarter and full year financial results on Tuesday, February 26, 2019, after the close of the financial markets.
With the holidays over and the JP Morgan Healthcare Conference next week, companies were clearly revving their engines, ready to race into the new year. Here’s a roundup of some of the top deals that were announced today.
Jazz Pharmaceuticals and Codiak BioSciences Announce Strategic Collaboration to Research, Develop and Commercialize Engineered Exosomes to Create Therapies for Hard-to-Treat Cancers
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Codiak BioSciences, Inc. today announced that the companies have entered into a strategic collaboration agreement focused on the research, development and commercialization of exosome therapeutics to treat cancer.
Jazz Pharmaceuticals Receives New PDUFA Goal Date for Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for its new drug application (NDA) for solriamfetol as a treatment to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
As the holidays approach, the U.S. Food and Drug Administration (FDA) is getting in a few drug approvals to wrap up the year. This week there are two decision dates, with another that has been delayed for several months. Here’s a look.
Jazz Pharmaceuticals plc today announced that its Board of Directors has authorized a $400 million increase in the company's share repurchase program, which the company intends to use over time based on market conditions and other factors.